Abstract
Since bortezomib was approved by the US Food and Drug Administration as the first proteasome inhibitor for the treatment of multiple myeloma (MM) ten years ago, proteasome inhibition has been established as an effective MM treatment strategy. However, some limitations have been found with bortezomib-based therapies, including bortezomib resistance (both intrinsic and acquired), severe toxicities (such as peripheral neuropathy), and unsatisfied efficacy in the treatment of solid tumors. In order to overcome the shortcomings of bortezomib, researchers have investigated the involved molecular mechanisms and developed novel strategies to improve proteasome inhibitor-based therapies and patient cares. This mini hot issue will review the current advances in the status of bortezomib, clinically tested second generation proteasome inhibitors, and preclinically developed proteasome inhibitors, and summarize some cutting-edge strategies in this field, including selective targeting immunoproteasomes, 19S deubiquitinases or ubiquitin E3 ligases, and developing novel combinational therapies. While there are still many new challenges ahead, the great progress in proteasome inhibitor therapy will definitely help illuminate the bright future of MM and other cancer management.
Current Cancer Drug Targets
Title:Editorial (Thematic Issue: Recent Advances in Proteasome Inhibitor-Based Cancer Therapies)
Volume: 14 Issue: 6
Author(s): Q. Ping Dou
Affiliation:
Abstract: Since bortezomib was approved by the US Food and Drug Administration as the first proteasome inhibitor for the treatment of multiple myeloma (MM) ten years ago, proteasome inhibition has been established as an effective MM treatment strategy. However, some limitations have been found with bortezomib-based therapies, including bortezomib resistance (both intrinsic and acquired), severe toxicities (such as peripheral neuropathy), and unsatisfied efficacy in the treatment of solid tumors. In order to overcome the shortcomings of bortezomib, researchers have investigated the involved molecular mechanisms and developed novel strategies to improve proteasome inhibitor-based therapies and patient cares. This mini hot issue will review the current advances in the status of bortezomib, clinically tested second generation proteasome inhibitors, and preclinically developed proteasome inhibitors, and summarize some cutting-edge strategies in this field, including selective targeting immunoproteasomes, 19S deubiquitinases or ubiquitin E3 ligases, and developing novel combinational therapies. While there are still many new challenges ahead, the great progress in proteasome inhibitor therapy will definitely help illuminate the bright future of MM and other cancer management.
Export Options
About this article
Cite this article as:
Dou Ping Q., Editorial (Thematic Issue: Recent Advances in Proteasome Inhibitor-Based Cancer Therapies), Current Cancer Drug Targets 2014; 14 (6) . https://dx.doi.org/10.2174/1568009614666140805163018
DOI https://dx.doi.org/10.2174/1568009614666140805163018 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry Inflammasome, Inflammation and Cancer: An Interrelated Pathobiological Triad
Current Drug Targets Safety of Nanoparticles in Medicine
Current Drug Targets Healing Effects of Curcumin Nanoparticles in Deep Tissue Injury Mouse Model
Current Drug Delivery Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies
Current Radiopharmaceuticals Too Much of a Good Thing: Suicide Prevention Promotes Chemoresistance in Ovarian Carcinoma
Current Cancer Drug Targets Engineering Considerations for Process Development in Mammalian Cell Cultivation
Current Pharmaceutical Biotechnology New Insights Toward Nanostructured Drug Delivery of Plant-Derived Polyphenol Compounds: Cancer Treatment and Gene Expression Profiles
Current Cancer Drug Targets The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Wnt/β-catenin Antagonists: Exploring New Avenues to Trigger Old Drugs in Alleviating Glioblastoma Multiforme
Current Molecular Pharmacology The Mechanism of Calcitriol in Cancer Prevention and Treatment
Current Medicinal Chemistry In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine Addressing the Challenge: Current and Future Directions in Ovarian Cancer Therapy
Current Gene Therapy Editorial: Epigenetics: A Novel Frontier For Drug Discovery
Current Medicinal Chemistry Marizomib, A Potent Second Generation Proteasome Inhibitor from Natural Origin
Anti-Cancer Agents in Medicinal Chemistry Targeting the Plasmodium Ubiquitin/Proteasome System with Anti- Malarial Compounds: Promises for the Future
Infectious Disorders - Drug Targets Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
Current Drug Targets IT-143, A Polymer Micelle Nanoparticle, Widens Therapeutic Window of Daunorubicin
Pharmaceutical Nanotechnology Cancer Chemopreventive Agents Discovered by Activity-Guided Fractionation: An Update
Current Organic Chemistry p38 MAP Kinase Inhibitors as Potential Therapeutic Drugs for Neural Diseases
Central Nervous System Agents in Medicinal Chemistry